December, 2017

PerSimiO is very pleased to announce that Prof. Aharon (Roni) Finestone has joined the Company as Chief Medical Officer.  Prof. Finestone is currently working part-time at the Assaf HaRofeh Medical Center, Israel.  He is an Associate Professor in Orthopedic Surgery at Sackler School of Medicine, Tel Aviv University.  Prof. Finestone is a board member of the Israel Orthopedic Society and serves as treasurer of the International Federation of Manual/Musculoskeletal Medicine.  Aharon has published approximately 100 original articles in peer reviewed journals and presented papers at more than 40 international conferences.

October, 2017

PerSimiO is pleased to announce that two new investors have invested funds into the Company.  With this financial support, PerSimiO will be able expand clinical trials, pursue CE and FDA certification, and continue development of its flagship solution, Simfini.  

August, 2017

PerSimiO welcomes a new member to the Company's Research and Development Team, Dr. Yehoshua Enuka, who specializes in big data analytics, statistics and machine learning techniques.  Yehoshua holds a BSc in Computer Science and a PhD in Structural Biology.  He recently completed a Postdoctoral Fellowship in Genomic Data Analysis at the Weizmann Institute of Science.  In addition, Yehoshua has published several peer reviewed papers in leading professional journals.

 

PerSimiO is pleased to announce that the Israel Innovation Authority (formerly the Office of the Chief Scientist) has awarded a second government grant in the amount of NIS 1.5 million (approximately USD 426K) to the Company.  The grant will be used in conjunction with additional invested capital to further the development of PerSimiO's proprietary orthopedic decision support system, Simfini. 

 

July, 2017

PerSimiO is pleased to announce that the Company's two initial investors have invested additional funds into the Company.  With this financial support, PerSimiO will be able to continue development of its flagship solution, Simfini.  These funds will also act as "matching funds" enabling PerSimiO to maximize a grant from the Office of the Chief Scientist.

 

March, 2017


PerSimiO Ltd. listed as a startup to "keep your eye on" by Tech7/SilicoNegev pitch competition in Beer Sheva.  SilicoNegev, sponsored by Tech7, has been hosting its first ever "southern startup" competition in Beer Sheva, hearing from the best and brightest of this up and coming hub of innovation led by the research at Ben Gurion University.   PerSimiO  started out the pitch competition as 1 of 50 startup companies competing for a 500,000 shekel investment.  After two rounds, PerSimiO was selected as 1 of 10 to continue in the competition. 
 

September, 2016

PerSimiO Ltd. welcomes a new member to our Research and Development Team.  Mr. Gilad Book joined PerSimiO. He holds a BSc in Mathematics and a MSc in Applied Mathematics.


March, 2016

PerSimiO Ltd. is pleased to announce two new investors in our company.


January 2, 2016


PerSimiO Ltd. is pleased to announce the addition of  Amir Sternheim, MD to the scientific board.  Dr. Sternheim is a Senior Orthopedic Surgeon, Orthopedic Oncology Department, Sourasky Medical Center, Tel-Aviv.  

December 24, 2015


PerSimiO Ltd. formed a new scientific board to include Prof. Moshe Salai, MD. Director, Orthopedic Division, Sourasky Medical Center, Tel Aviv and  – Chairman ,Department of Radiology Hadassah Medical Center, Jerusalem.

October 20, 2015


PerSimiO Ltd. was awarded a government grant of approximately NIS 2.3 million (approximately USD 529K) from the Office of the Chief Scientist (OCS) at the Ministry of Economy of Israel.

The grant will be used to cover R&D expenses for a 12-month period to support further development and commercialization of the Company's proprietary orthopedic decision support system Simfini.

The OCS awards grants to companies from various industries in Israel to foster technological innovations. Recipient selections are based on multiple criteria including the uniqueness of a company's technology, and the potential market it addresses, plus the robustness of the company's business including financial position, R&D capabilities and management experience.